Est. 2026 — Visceral Fat & Metabolic Risk Layer

The clinical target at the
core of metabolic medicine.

Viscix builds the data infrastructure for companies measuring, monitoring, and treating visceral adiposity — the primary clinical target of GLP-1 therapy and the central driver of metabolic disease.

Visceral (Latin: viscera) — the organs within. The fat surrounding them is the most clinically significant measurement in metabolic medicine today.
#1 Visceral fat reduction — primary endpoint of GLP-1 clinical trials
2.6× Higher cardiovascular mortality risk with elevated visceral adiposity
$180B Global metabolic disease management market by 2028

// Core infrastructure

01

Visceral fat quantification

Standardized visceral adiposity measurement pipelines integrating DEXA, MRI, and surrogate biomarker estimation — built for GLP-1 clinics, obesity medicine practices, and cardiometabolic research.

02

Treatment response tracking

Longitudinal visceral fat reduction analytics across GLP-1 treatment cohorts. Viscix provides the outcomes infrastructure for clinical research, real-world evidence, and payer reporting.

03

Cardiometabolic risk API

Integrate visceral adiposity index, metabolic syndrome scoring, and cardiovascular risk stratification into your clinical platform via a single API — no custom biostatistics required.

// Why now

Visceral fat is the clinical endpoint that defines the GLP-1 era. No one has built the infrastructure around it.

V

Every major GLP-1 clinical trial measures visceral fat reduction as its primary endpoint. Every cardiometabolic risk model depends on visceral adiposity. Every obesity medicine physician wants longitudinal visceral fat data on their patients. And yet the infrastructure to capture, standardize, and analyze this data at scale simply does not exist.

Viscix fills that gap. We provide the data pipelines, measurement standardization, and analytics layer that GLP-1 clinics, obesity medicine platforms, pharmaceutical outcomes teams, and cardiometabolic risk companies need to operate at clinical scale.

The GLP-1 market is moving faster than any healthcare category in history. The companies that win will be the ones with the best data infrastructure underneath them.

// Get in touch

Work with
Viscix

We are selectively onboarding infrastructure partners and early customers. Tell us about your platform and what you are building in metabolic and visceral health.

// We respond within 48 hours. No sales calls without consent.